ECO Animal Health’s lead product, Aivlosin®, continues to generate strong growth in multiple geographies. The recent additional product approvals in the US and Europe along with prospective new market opportunities provide an attractive outlook. We estimate a c.15% 3 year CAGR for Aivlosin® sales, with new marketing authorisations providing upside potential. We initiate coverage with a 498p Target Price and a Buy recommendation.
11 Aug 2016
N+1 Singer - ECO Animal Health Group - Aivlosin® growth set to continue
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - ECO Animal Health Group - Aivlosin® growth set to continue
ECO Animal Health Group plc (EAH:LON) | 94.0 0 0.0% | Mkt Cap: 63.7m
- Published:
11 Aug 2016 -
Author:
Sheena Berry -
Pages:
17
ECO Animal Health’s lead product, Aivlosin®, continues to generate strong growth in multiple geographies. The recent additional product approvals in the US and Europe along with prospective new market opportunities provide an attractive outlook. We estimate a c.15% 3 year CAGR for Aivlosin® sales, with new marketing authorisations providing upside potential. We initiate coverage with a 498p Target Price and a Buy recommendation.